董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Margaret Smith Bell | 女 | Director | 61 | 7.38万美元 | 未持股 | 2021-03-31 |
| Daniel Goodman | -- | Director | 60 | 7.38万美元 | 未持股 | 2021-03-31 |
| David Grange | 男 | Director | 73 | 7.38万美元 | 未持股 | 2021-03-31 |
| Adeoye Olukotun | 男 | Director | 76 | 7.38万美元 | 未持股 | 2021-03-31 |
| James Treco | 男 | Lead Director | 65 | 10.18万美元 | 未持股 | 2021-03-31 |
| Richard Bagger | 男 | Director | 61 | 6.30万美元 | 未持股 | 2021-03-31 |
| Seth Lederman | 男 | President, CEO and Chairman of the Board | 63 | 387.48万美元 | 未持股 | 2021-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregory Sullivan | 男 | Chief Medical Officer and Secretary | 55 | 138.24万美元 | 未持股 | 2021-03-31 |
| Bradley Saenger | 男 | Chief Financial Officer and Treasurer | 47 | 109.18万美元 | 未持股 | 2021-03-31 |
| Jessica Morris | 女 | Chief Operating Officer | 43 | 未披露 | 未持股 | 2021-03-31 |
| Seth Lederman | 男 | President, CEO and Chairman of the Board | 63 | 387.48万美元 | 未持股 | 2021-03-31 |
董事简历
中英对照 | 中文 | 英文- Margaret Smith Bell
-
Margaret Smith Bell于2017年9月成为董事。Bell女士已经退休十年了。此前，贝尔女士是标准人寿投资公司（Standard Life Investments）的Vice President，她在该公司担任投资组合经理和医疗保健股票分析师。Bell女士也是Putnam Investments的常务董事，并担任Putnam Health Sciences Trust的高级医疗保健分析师和投资组合经理。Bell女士是State Street Research的分析师和Vice President，也是Alex.Brown&Sons，Inc.的研究分析师。Bell女士是贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）监督员委员会的前任成员。Bell女士拥有卫斯理大学（Wesleyan University）的学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）的工商管理硕士学位。
Margaret Smith Bell became a Director in September 2017. Ms. Bell has been retired for the last ten years. Previously, Ms. Bell was a Vice President at Standard Life Investments where she was a portfolio manager and health care equity analyst. Ms. Bell was also a Managing Director at Putnam Investments, and served as a senior health care analyst and a portfolio manager of the Putnam Health Sciences Trust. Ms. Bell was an analyst and vice president at State Street Research and a research analyst at Alex. Brown & Sons, Inc. Ms. Bell is a past member of the Board of Overseers at Beth Israel Deaconess Medical Center. Ms. Bell holds a B.A. from Wesleyan University and an M.B.A. from the Wharton School at the University of Pennsylvania. - Margaret Smith Bell于2017年9月成为董事。Bell女士已经退休十年了。此前，贝尔女士是标准人寿投资公司（Standard Life Investments）的Vice President，她在该公司担任投资组合经理和医疗保健股票分析师。Bell女士也是Putnam Investments的常务董事，并担任Putnam Health Sciences Trust的高级医疗保健分析师和投资组合经理。Bell女士是State Street Research的分析师和Vice President，也是Alex.Brown&Sons，Inc.的研究分析师。Bell女士是贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）监督员委员会的前任成员。Bell女士拥有卫斯理大学（Wesleyan University）的学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）的工商管理硕士学位。
- Margaret Smith Bell became a Director in September 2017. Ms. Bell has been retired for the last ten years. Previously, Ms. Bell was a Vice President at Standard Life Investments where she was a portfolio manager and health care equity analyst. Ms. Bell was also a Managing Director at Putnam Investments, and served as a senior health care analyst and a portfolio manager of the Putnam Health Sciences Trust. Ms. Bell was an analyst and vice president at State Street Research and a research analyst at Alex. Brown & Sons, Inc. Ms. Bell is a past member of the Board of Overseers at Beth Israel Deaconess Medical Center. Ms. Bell holds a B.A. from Wesleyan University and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Daniel Goodman
-
Daniel Goodman于2019年5月成为董事。Goodman博士于2012年创立了Riverside Pharmaceuticals，这是一家药物发现公司，并自成立以来一直担任其首席执行官。Goodman博士于1998年共同创立了Psychogenics Inc.，该公司是一家临床前神经药理学公司，从1998年到2000年担任其首席执行官，并自2000年以来一直在其董事会任职。Goodman博士毕业于哈佛医学院（Harvard Medical School），并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
Daniel Goodman became a Director in May 2019. Dr. Goodman founded Riverside Pharmaceuticals, a drug discovery company, in 2012 and has been its Chief Executive Officer since inception. Dr. Goodman co-founded PsychoGenics Inc., a preclinical neuropharmacology company, in 1998 was its Chief Executive Officer from 1998 to 2000 and has served on its Board of Directors since 2000. Dr. Goodman is also a practicing physician and has been President and cofounder of The Midtown Practice for Psychiatry PC since 2017 and President and founder of Daniel Goodman MD PC since 2003. Dr. Goodman graduated from Harvard Medical School and has an M.B.A. from Columbia Business School. - Daniel Goodman于2019年5月成为董事。Goodman博士于2012年创立了Riverside Pharmaceuticals，这是一家药物发现公司，并自成立以来一直担任其首席执行官。Goodman博士于1998年共同创立了Psychogenics Inc.，该公司是一家临床前神经药理学公司，从1998年到2000年担任其首席执行官，并自2000年以来一直在其董事会任职。Goodman博士毕业于哈佛医学院（Harvard Medical School），并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- Daniel Goodman became a Director in May 2019. Dr. Goodman founded Riverside Pharmaceuticals, a drug discovery company, in 2012 and has been its Chief Executive Officer since inception. Dr. Goodman co-founded PsychoGenics Inc., a preclinical neuropharmacology company, in 1998 was its Chief Executive Officer from 1998 to 2000 and has served on its Board of Directors since 2000. Dr. Goodman is also a practicing physician and has been President and cofounder of The Midtown Practice for Psychiatry PC since 2017 and President and founder of Daniel Goodman MD PC since 2003. Dr. Goodman graduated from Harvard Medical School and has an M.B.A. from Columbia Business School.
- David Grange
-
David Grange美国陆军于2018年2月退休，成为董事。BG Grange自2011年起担任服务伤残退伍军人组织Osprey Global Solutions，LLC（“；OGS”；）总裁和创始人。BG Grange于2017年4月至2019年10月担任合同研究组织Pharm-Olam International，Ltd.（“；Pharm-Olam”；）的首席执行官。在创立OGS之前，BG Grange于2003年至2009年担任合同研究组织Pharmaceutical ProductDevelopment，Inc.（PPDI）的董事会成员，并于2009年至2011年担任首席执行官。任职PPDI公司之前，他曾任职McCormick Tribune Foundation10年，最近担任首席执行官兼总裁，在那里他也曾监管老兵项目的支持。步兵和特种作战部队的成员。在五角大楼，他是陆军当前行动，准备和动员主任。BG田庄指挥游骑兵团和第一步兵师（大红之一）。BG Grange持有Western Kentucky University公共服务硕士学位。
David Grange became a director in February 2018. BG Grange has been President and founder of Osprey Global Solutions, LLC “OGS”, a Service Disabled Veterans Organization, since 2011. BG Grange was Chief Executive Officer of Pharm-Olam International, Ltd. (“Pharm-Olam”), a contract research organization, from April 2017 to October 2019. Prior to founding OGS, BG Grange was a member of the Board of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), a contract research organization, from 2003 to 2009 and Chief Executive Officer from 2009 to 2011. Prior to PPDI he served in the McCormick Tribune Foundation for 10 years most recently as Chief Executive Officer and President, where he also oversaw the support of Veteran Programs.BG Grange served 30 years in the U.S. Army as a Ranger, Green Beret, Aviator, Infantryman and a member of special operating units. At the Pentagon, he was Director of Army Current Operations, Readiness, and Mobilization.BG Grange commanded the Ranger Regiment and the First Infantry Division (the Big Red One).BG Grange holds a master’s degree in Public Service from Western Kentucky University. - David Grange美国陆军于2018年2月退休，成为董事。BG Grange自2011年起担任服务伤残退伍军人组织Osprey Global Solutions，LLC（“；OGS”；）总裁和创始人。BG Grange于2017年4月至2019年10月担任合同研究组织Pharm-Olam International，Ltd.（“；Pharm-Olam”；）的首席执行官。在创立OGS之前，BG Grange于2003年至2009年担任合同研究组织Pharmaceutical ProductDevelopment，Inc.（PPDI）的董事会成员，并于2009年至2011年担任首席执行官。任职PPDI公司之前，他曾任职McCormick Tribune Foundation10年，最近担任首席执行官兼总裁，在那里他也曾监管老兵项目的支持。步兵和特种作战部队的成员。在五角大楼，他是陆军当前行动，准备和动员主任。BG田庄指挥游骑兵团和第一步兵师（大红之一）。BG Grange持有Western Kentucky University公共服务硕士学位。
- David Grange became a director in February 2018. BG Grange has been President and founder of Osprey Global Solutions, LLC “OGS”, a Service Disabled Veterans Organization, since 2011. BG Grange was Chief Executive Officer of Pharm-Olam International, Ltd. (“Pharm-Olam”), a contract research organization, from April 2017 to October 2019. Prior to founding OGS, BG Grange was a member of the Board of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), a contract research organization, from 2003 to 2009 and Chief Executive Officer from 2009 to 2011. Prior to PPDI he served in the McCormick Tribune Foundation for 10 years most recently as Chief Executive Officer and President, where he also oversaw the support of Veteran Programs.BG Grange served 30 years in the U.S. Army as a Ranger, Green Beret, Aviator, Infantryman and a member of special operating units. At the Pentagon, he was Director of Army Current Operations, Readiness, and Mobilization.BG Grange commanded the Ranger Regiment and the First Infantry Division (the Big Red One).BG Grange holds a master’s degree in Public Service from Western Kentucky University.
- Adeoye Olukotun
-
Adeoye Olukotun于2018年9月成为董事。Olukotun博士自2000年以来一直担任医疗产品咨询公司CR Strategies，LLC的首席执行官，并于2014年至2018年1月担任制药公司Epigen Pharmaceuticals，Inc.的首席执行官。Olukotun博士于2012年至2016年担任制药公司Cardovax，Inc.的副董事长，并于2006年至2012年担任其首席执行官。他还是制药公司Via Pharmaceuticals，Inc.的联合创始人，从2004年到2008年担任该公司的首席医疗官。
Adeoye Olukotun,is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development , since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health. - Adeoye Olukotun于2018年9月成为董事。Olukotun博士自2000年以来一直担任医疗产品咨询公司CR Strategies，LLC的首席执行官，并于2014年至2018年1月担任制药公司Epigen Pharmaceuticals，Inc.的首席执行官。Olukotun博士于2012年至2016年担任制药公司Cardovax，Inc.的副董事长，并于2006年至2012年担任其首席执行官。他还是制药公司Via Pharmaceuticals，Inc.的联合创始人，从2004年到2008年担任该公司的首席医疗官。
- Adeoye Olukotun,is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development , since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health.
- James Treco
-
James Treco于2019年2月成为董事，自2020年3月起担任首席董事。他曾一直担任First Chicago Advisors公司（精品金融咨询公司）的管理合伙人，在那里他曾为多种公司（从全球大型公司到新兴公司）的高管和董事会提供建议（2009年至2012年、2014年至今）。从2012年到2013年，Treco先生是Gleacher&Company的投资银行家，该公司先前经营投资银行业务，为企业和机构客户提供战略和财务咨询服务。从1984年到2008年，Treco先生在所罗门兄弟（Salomon Brothers）/花旗集团（Citigroup）担任各种职责递增的职位，在那里他利用他在全球资本市场的丰富经验为广泛的客户提供建议。Treco先生拥有耶鲁大学（Yale University）的学士学位和斯坦福大学商学院（Stanford University Graduate School of Business）的工商管理硕士学位。
James Treco became a director in February 2019 and has been our Lead Director since March 2020. Mr. Treco has been a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global, large-cap companies to emerging companies, from 2009 to 2012 and from 2014 to the present. From 2012 to 2013 Mr. Treco was an investment banker with Gleacher & Company, a company that previously operated an investment banking business, providing corporate and institutional clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon Brothers/Citigroup from 1984 to 2008 where he used his extensive experience in the global capital markets to advise a wide range of clients. Mr. Treco holds a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business. - James Treco于2019年2月成为董事，自2020年3月起担任首席董事。他曾一直担任First Chicago Advisors公司（精品金融咨询公司）的管理合伙人，在那里他曾为多种公司（从全球大型公司到新兴公司）的高管和董事会提供建议（2009年至2012年、2014年至今）。从2012年到2013年，Treco先生是Gleacher&Company的投资银行家，该公司先前经营投资银行业务，为企业和机构客户提供战略和财务咨询服务。从1984年到2008年，Treco先生在所罗门兄弟（Salomon Brothers）/花旗集团（Citigroup）担任各种职责递增的职位，在那里他利用他在全球资本市场的丰富经验为广泛的客户提供建议。Treco先生拥有耶鲁大学（Yale University）的学士学位和斯坦福大学商学院（Stanford University Graduate School of Business）的工商管理硕士学位。
- James Treco became a director in February 2019 and has been our Lead Director since March 2020. Mr. Treco has been a Managing Partner at First Chicago Advisors, Inc., a boutique financial advisory firm where he advises executives and boards of directors of a wide range of companies, from global, large-cap companies to emerging companies, from 2009 to 2012 and from 2014 to the present. From 2012 to 2013 Mr. Treco was an investment banker with Gleacher & Company, a company that previously operated an investment banking business, providing corporate and institutional clients with strategic and financial advisory services. Mr. Treco held various positions of increasing responsibility at Salomon Brothers/Citigroup from 1984 to 2008 where he used his extensive experience in the global capital markets to advise a wide range of clients. Mr. Treco holds a B.A. from Yale University and an M.B.A. from the Stanford University Graduate School of Business.
- Richard Bagger
-
Richard Bagger于2020年6月成为董事。自2020年1月以来，Bagger先生一直是新泽西州咨询公司Christie55Solutions，LLC的合伙人兼执行董事。自2018年以来，Bagger先生还一直是罗格斯大学伊格尔顿研究所的兼职教员。从2012年到2019年，Bagger先生担任全球生物制药公司新基医药公司NASDAQ:CELG的公司事务和市场准入执行副总裁，也是其执行委员会的成员。从1993年到2010年，Bagger先生在辉瑞公司（纽约证券交易所代码:PFE）担任越来越重要的职位，这是一家全球性的制药公司，并从2006年到2009年担任全球公共事务和政策高级副总裁。在加入Pfizer之前，Bagger先生是Blue Cross and Blue Shield of New Jersey（一家健康保险公司）的助理总法律顾问，并在McCarter&English律师事务所从事法律工作。Bagger先生曾担任2019年国家制药委员会主席，也是美国商会董事会成员。他也是罗格斯大学商学院Lerner Center for the Study of Pharmaceutical Management Issues的顾问委员会成员。Bagger先生获得普林斯顿大学伍德罗·威尔逊公共和国际事务学院的A.B.学位和罗格斯大学法学院的J.D.学位。
Richard Bagger became a Director in June 2020. Mr. Bagger has been a Partner and Executive Director of Christie 55 Solutions, LLC, a New Jersey based consulting firm, since January 2020. Mr. Bagger has also been an Adjunct Faculty member at the Rutgers University Eagleton Institute since 2018. From 2012 through 2019 Mr. Bagger was Executive Vice President of Corporate Affairs and Market Access for Celgene Corporation NASDAQ: CELG, a global biopharmaceutical company, as well as a member of its Executive Committee. From 1993 to 2010 Mr. Bagger held roles of increasing responsibility with Pfizer Inc. (NYSE: PFE), a global pharmaceutical company, and served as Senior Vice President, Worldwide Public Affairs and Policy, from 2006 to 2009. Prior to joining Pfizer, Mr. Bagger was Assistant General Counsel of Blue Cross and Blue Shield of New Jersey, a health insurer, and practiced law with the law firm of McCarter & English. Mr. Bagger served as Board Chair of the National Pharmaceutical Council for 2019 and is a member of the Board of Directors of the U.S. Chamber of Commerce. He is also on the advisory board for the Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers University Business School. Mr. Bagger received an A.B. degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a J.D. degree from Rutgers University Law School. - Richard Bagger于2020年6月成为董事。自2020年1月以来，Bagger先生一直是新泽西州咨询公司Christie55Solutions，LLC的合伙人兼执行董事。自2018年以来，Bagger先生还一直是罗格斯大学伊格尔顿研究所的兼职教员。从2012年到2019年，Bagger先生担任全球生物制药公司新基医药公司NASDAQ:CELG的公司事务和市场准入执行副总裁，也是其执行委员会的成员。从1993年到2010年，Bagger先生在辉瑞公司（纽约证券交易所代码:PFE）担任越来越重要的职位，这是一家全球性的制药公司，并从2006年到2009年担任全球公共事务和政策高级副总裁。在加入Pfizer之前，Bagger先生是Blue Cross and Blue Shield of New Jersey（一家健康保险公司）的助理总法律顾问，并在McCarter&English律师事务所从事法律工作。Bagger先生曾担任2019年国家制药委员会主席，也是美国商会董事会成员。他也是罗格斯大学商学院Lerner Center for the Study of Pharmaceutical Management Issues的顾问委员会成员。Bagger先生获得普林斯顿大学伍德罗·威尔逊公共和国际事务学院的A.B.学位和罗格斯大学法学院的J.D.学位。
- Richard Bagger became a Director in June 2020. Mr. Bagger has been a Partner and Executive Director of Christie 55 Solutions, LLC, a New Jersey based consulting firm, since January 2020. Mr. Bagger has also been an Adjunct Faculty member at the Rutgers University Eagleton Institute since 2018. From 2012 through 2019 Mr. Bagger was Executive Vice President of Corporate Affairs and Market Access for Celgene Corporation NASDAQ: CELG, a global biopharmaceutical company, as well as a member of its Executive Committee. From 1993 to 2010 Mr. Bagger held roles of increasing responsibility with Pfizer Inc. (NYSE: PFE), a global pharmaceutical company, and served as Senior Vice President, Worldwide Public Affairs and Policy, from 2006 to 2009. Prior to joining Pfizer, Mr. Bagger was Assistant General Counsel of Blue Cross and Blue Shield of New Jersey, a health insurer, and practiced law with the law firm of McCarter & English. Mr. Bagger served as Board Chair of the National Pharmaceutical Council for 2019 and is a member of the Board of Directors of the U.S. Chamber of Commerce. He is also on the advisory board for the Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers University Business School. Mr. Bagger received an A.B. degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a J.D. degree from Rutgers University Law School.
- Seth Lederman
-
Seth Lederman，2011年10月担任董事长、首席执行官、董事会主席和总裁。2007年6月，Lederman创立Tonix Pharmaceuticals, Inc.（Tonix Sub全资子公司），并担任董事会主席；2010年6月起担任董事长。Lederman是一位拥有关键专利和潜在项目专利的发明家，包括治疗纤维肌痛症TNX-102 SL fibromyalgia、创伤后应激障碍的TNX-102 SL、发作性紧张型头痛 TNX-201以及酒精中毒TNX-301。2010年8月Krele成立，Lederman担任其主席。自2013年4月Tonix Pharmaceuticals （Canada）， Inc.成立起，Lederman担任董事长和总裁；2013年12月起，他担任Tonix Pharmaceuticals （Barbados）， Ltd总裁；2014年12月起，他担任Tonix Pharma Limited和Tonix Pharma Holdings Limited总裁。1996年起，Lederman担任Columbia University副教授。期间，Lederman发现并标明了CD40-ligand的特征，还发明了治疗自身免疫性疾病和移植排斥的治疗候选人。1996年起，Lederman担任L&L Technologies LLC或L&L经理。2007年1月起，Lederman担任Seth Lederman Co, LLC管理成员；2002年去担任Lederman & Co, LLC或Lederman & Co管理成员，两家公司均为生物制药咨询和投资公司。2000年起，Lederman还是Targent Pharmaceuticals, LLC, or Targent管理成员；2002年起，他是Plumbline LLC管理成员。2001年，Targent创立Targent Pharmaceuticals Inc.并担任董事会成员直到2006年被Spectrum Pharmaceuticals Inc.收购。2007年1月到2008年11月，Lederman是Konanda Pharma Partners, LLC执行合伙人、Konanda Pharma Fund I, LP董事长以及Konanda General Partner, LLC普通合伙人，它们都是相互关联的私人股本基金实体。2007年1月到2008年11月，Lederman是Validus Pharmaceuticals, Inc.和Fontus Pharmaceuticals, Inc.主席，它们是Konanda私人增长股票型基金投资组合公司。2011年12月起，Lederman担任Leder Laboratories Inc.，或Leder Labs, and Starling Pharmaceuticals Inc.或Starling（均为生物制药开发公司）首席执行官和主席。2013年3月起，Lederman担任Leder Laboratories, Ltd.（Leder Laboratories Inc.全资子公司）主席；2006年到2011年，他是Research Corporation（一个总部位于纽约的非营利性组织）董事长。1979年，Lederman获得Princeton University化学学士学位；1983年，他获得Columbia University硕士学位。1985年起，Lederman成为纽约州注册医生。
Seth Lederman became our President, Chief Executive Officer, Chairman of the Board and a Director in October 2011. Dr. Lederman founded Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of us “Tonix Sub” in 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since 2010. Dr. Lederman is an inventor on key patents and patent applications underlying our programs including: TNX-102 SL’s eutectic composition; TNX-102 SL’s pharmacokinetic profile and related therapeutic properties, and the use of TNX-102 SL for posttraumatic stress disorder (PTSD). Dr. Lederman served as an Associate Professor at Columbia University, between 1996 and 2017. As an Assistant Professor at Columbia, Dr. Lederman discovered and characterized the CD40-ligand, or CD154 and invented therapeutic candidates to treat autoimmune diseases and transplant rejection. TNX-1500 is a monoclonal antibody directed against CD154 invented by Dr. Lederman. Dr. Lederman has been a Manager of L&L Technologies LLC, or L&L, since 1996. In addition, Dr. Lederman has been the Managing Member of Seth Lederman Co, LLC since 2007 and the Managing Member of Lederman & Co, LLC, or Lederman & Co, since 2002 both of which are biopharmaceutical consulting and investing companies. Dr. Lederman has also been the Managing Member of Targent Pharmaceuticals, LLC, or Targent, since 2000 and Managing Member of Plumbline LLC since 2002. Targent was a founder of Targent Pharmaceuticals Inc. on which Board of Directors Dr. Lederman served from inception in 2001 until the sale of its assets to Spectrum Pharmaceuticals Inc. in 2006. Between January 2007 and November 2008 Dr. Lederman was a Managing Partner of Konanda Pharma Partners, LLC, a Director of Konanda Pharma Fund I, LP, and a Managing Partner of Konanda General Partner, LLC, which were related private growth equity fund entities. As well, between 2007 and 2008 Dr. Lederman was Chairman of Validus Pharmaceuticals, Inc. and Fontus Pharmaceuticals, Inc., which were portfolio companies of the Konanda private growth equity funds. Since 2011 Dr. Lederman has served as CEO and Chairman of Leder Laboratories Inc., or Leder Labs, and Starling Pharmaceuticals Inc., or Starling, which are biopharmaceutical development companies. Dr. Lederman was the chairman of Leder Laboratories, Ltd., a wholly-owned subsidiary of Leder Laboratories Inc., between 2013 and 2018 when the entity was dissolved. In 2015 Dr. Lederman served as a member of the US - Japan Business Council. Between 2006 and 2011 Dr. Lederman was a director of Research Corporation, a New York-based non-profit organization. Dr. Lederman received his BA degree in Chemistry from Princeton University in 1979 and his MD from Columbia University in 1983. - Seth Lederman，2011年10月担任董事长、首席执行官、董事会主席和总裁。2007年6月，Lederman创立Tonix Pharmaceuticals, Inc.（Tonix Sub全资子公司），并担任董事会主席；2010年6月起担任董事长。Lederman是一位拥有关键专利和潜在项目专利的发明家，包括治疗纤维肌痛症TNX-102 SL fibromyalgia、创伤后应激障碍的TNX-102 SL、发作性紧张型头痛 TNX-201以及酒精中毒TNX-301。2010年8月Krele成立，Lederman担任其主席。自2013年4月Tonix Pharmaceuticals （Canada）， Inc.成立起，Lederman担任董事长和总裁；2013年12月起，他担任Tonix Pharmaceuticals （Barbados）， Ltd总裁；2014年12月起，他担任Tonix Pharma Limited和Tonix Pharma Holdings Limited总裁。1996年起，Lederman担任Columbia University副教授。期间，Lederman发现并标明了CD40-ligand的特征，还发明了治疗自身免疫性疾病和移植排斥的治疗候选人。1996年起，Lederman担任L&L Technologies LLC或L&L经理。2007年1月起，Lederman担任Seth Lederman Co, LLC管理成员；2002年去担任Lederman & Co, LLC或Lederman & Co管理成员，两家公司均为生物制药咨询和投资公司。2000年起，Lederman还是Targent Pharmaceuticals, LLC, or Targent管理成员；2002年起，他是Plumbline LLC管理成员。2001年，Targent创立Targent Pharmaceuticals Inc.并担任董事会成员直到2006年被Spectrum Pharmaceuticals Inc.收购。2007年1月到2008年11月，Lederman是Konanda Pharma Partners, LLC执行合伙人、Konanda Pharma Fund I, LP董事长以及Konanda General Partner, LLC普通合伙人，它们都是相互关联的私人股本基金实体。2007年1月到2008年11月，Lederman是Validus Pharmaceuticals, Inc.和Fontus Pharmaceuticals, Inc.主席，它们是Konanda私人增长股票型基金投资组合公司。2011年12月起，Lederman担任Leder Laboratories Inc.，或Leder Labs, and Starling Pharmaceuticals Inc.或Starling（均为生物制药开发公司）首席执行官和主席。2013年3月起，Lederman担任Leder Laboratories, Ltd.（Leder Laboratories Inc.全资子公司）主席；2006年到2011年，他是Research Corporation（一个总部位于纽约的非营利性组织）董事长。1979年，Lederman获得Princeton University化学学士学位；1983年，他获得Columbia University硕士学位。1985年起，Lederman成为纽约州注册医生。
- Seth Lederman became our President, Chief Executive Officer, Chairman of the Board and a Director in October 2011. Dr. Lederman founded Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of us “Tonix Sub” in 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since 2010. Dr. Lederman is an inventor on key patents and patent applications underlying our programs including: TNX-102 SL’s eutectic composition; TNX-102 SL’s pharmacokinetic profile and related therapeutic properties, and the use of TNX-102 SL for posttraumatic stress disorder (PTSD). Dr. Lederman served as an Associate Professor at Columbia University, between 1996 and 2017. As an Assistant Professor at Columbia, Dr. Lederman discovered and characterized the CD40-ligand, or CD154 and invented therapeutic candidates to treat autoimmune diseases and transplant rejection. TNX-1500 is a monoclonal antibody directed against CD154 invented by Dr. Lederman. Dr. Lederman has been a Manager of L&L Technologies LLC, or L&L, since 1996. In addition, Dr. Lederman has been the Managing Member of Seth Lederman Co, LLC since 2007 and the Managing Member of Lederman & Co, LLC, or Lederman & Co, since 2002 both of which are biopharmaceutical consulting and investing companies. Dr. Lederman has also been the Managing Member of Targent Pharmaceuticals, LLC, or Targent, since 2000 and Managing Member of Plumbline LLC since 2002. Targent was a founder of Targent Pharmaceuticals Inc. on which Board of Directors Dr. Lederman served from inception in 2001 until the sale of its assets to Spectrum Pharmaceuticals Inc. in 2006. Between January 2007 and November 2008 Dr. Lederman was a Managing Partner of Konanda Pharma Partners, LLC, a Director of Konanda Pharma Fund I, LP, and a Managing Partner of Konanda General Partner, LLC, which were related private growth equity fund entities. As well, between 2007 and 2008 Dr. Lederman was Chairman of Validus Pharmaceuticals, Inc. and Fontus Pharmaceuticals, Inc., which were portfolio companies of the Konanda private growth equity funds. Since 2011 Dr. Lederman has served as CEO and Chairman of Leder Laboratories Inc., or Leder Labs, and Starling Pharmaceuticals Inc., or Starling, which are biopharmaceutical development companies. Dr. Lederman was the chairman of Leder Laboratories, Ltd., a wholly-owned subsidiary of Leder Laboratories Inc., between 2013 and 2018 when the entity was dissolved. In 2015 Dr. Lederman served as a member of the US - Japan Business Council. Between 2006 and 2011 Dr. Lederman was a director of Research Corporation, a New York-based non-profit organization. Dr. Lederman received his BA degree in Chemistry from Princeton University in 1979 and his MD from Columbia University in 1983.
高管简历
中英对照 | 中文 | 英文- Gregory Sullivan
Gregory Sullivan，2014年6月3日，成为本公司的首席医学官。此前，他从2010年10月起，担任本公司的科学顾问委员会成员，也曾提供专门的咨询服务。此前，他从1999年7月起，担任Columbia University的教员，并在该校Columbia University Medical Center CUMC的精神病学系担任精神病学助理教授，直到2014年6月。1997年6月至2014年8月，他继续兼职精神病学的从医工作。2006年12月至2014年6月，他是New York State Psychiatric Institute （NYSPI）的研究科学家。2009年1月至2014年6月，他还是NYPI机构评审委员会的成员。作为一些人体创伤后应激障碍研究的首席调查员、联席调查员，他曾负责管理这些调查临床试验的招聘、生物评估、以及参与者的治疗和安全。他出版了50多篇研究性的论文和书籍章节，涉及课题从紧张、焦虑障碍，到抑郁症、创伤后应激障碍、惊恐障碍的异常血清素受体表达。他曾受到多个机构的资助：National Institute of Mental Health （NIMH）、the Anxiety Disorders Association of America、NARSAD、Dana Foundation、American Foundation for Suicide Prevention。他在University of California, Berkeley获得生物学士学位，在College of Physicians & Surgeons at Columbia University获得医学博士学位，在CUMC完成精神病学驻院实习，并在NIMH的资助下进行了2年的焦虑和情感性精神障碍研究工作；此后他成为该校教员。
Gregory Sullivan became our Chief Medical Officer on June 3 2014 and our Secretary in March 2017. Prior to becoming our Chief Medical Officer, he served on our Scientific Advisory Board since October 2010 and had also provided ad hoc consulting services. Previously, Dr. Sullivan had been a member of the faculty of Columbia University since July 1999 where he served as an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University Medical Center CUMC until June 2014. Between June 1997 and August 2014 Dr. Sullivan maintained a part-time psychiatry practice. He served as a Research Scientist at the New York State Psychiatric Institute (NYSPI) from December 2006 to June 2014. He also served as a member of the Institutional Review Board of the NYSPI from January 2009 to June 2014. As Principal Investigator and Co-Investigator on several human studies of PTSD, Dr. Sullivan has administered the recruitment, biological assessments, treatment, and safety of participants with PTSD in clinical trials of the disorder. He has published more than 50 articles and chapters on research topics ranging from stress and anxiety disorders to abnormal serotonin receptor expression in depression, PTSD and panic disorder. He is a recipient of grants from the National Institute of Mental Health (NIMH), the Anxiety Disorders Association of America, NARSAD, the Dana Foundation, and the American Foundation for Suicide Prevention. Dr. Sullivan received a BA in Biology from the University of California, Berkeley, and received his MD from the College of Physicians & Surgeons at Columbia University. He completed his residency training in psychiatry at CUMC, and then a two-year NIMH-sponsored research fellowship in anxiety and affective disorders before joining the faculty at Columbia.- Gregory Sullivan，2014年6月3日，成为本公司的首席医学官。此前，他从2010年10月起，担任本公司的科学顾问委员会成员，也曾提供专门的咨询服务。此前，他从1999年7月起，担任Columbia University的教员，并在该校Columbia University Medical Center CUMC的精神病学系担任精神病学助理教授，直到2014年6月。1997年6月至2014年8月，他继续兼职精神病学的从医工作。2006年12月至2014年6月，他是New York State Psychiatric Institute （NYSPI）的研究科学家。2009年1月至2014年6月，他还是NYPI机构评审委员会的成员。作为一些人体创伤后应激障碍研究的首席调查员、联席调查员，他曾负责管理这些调查临床试验的招聘、生物评估、以及参与者的治疗和安全。他出版了50多篇研究性的论文和书籍章节，涉及课题从紧张、焦虑障碍，到抑郁症、创伤后应激障碍、惊恐障碍的异常血清素受体表达。他曾受到多个机构的资助：National Institute of Mental Health （NIMH）、the Anxiety Disorders Association of America、NARSAD、Dana Foundation、American Foundation for Suicide Prevention。他在University of California, Berkeley获得生物学士学位，在College of Physicians & Surgeons at Columbia University获得医学博士学位，在CUMC完成精神病学驻院实习，并在NIMH的资助下进行了2年的焦虑和情感性精神障碍研究工作；此后他成为该校教员。
- Gregory Sullivan became our Chief Medical Officer on June 3 2014 and our Secretary in March 2017. Prior to becoming our Chief Medical Officer, he served on our Scientific Advisory Board since October 2010 and had also provided ad hoc consulting services. Previously, Dr. Sullivan had been a member of the faculty of Columbia University since July 1999 where he served as an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University Medical Center CUMC until June 2014. Between June 1997 and August 2014 Dr. Sullivan maintained a part-time psychiatry practice. He served as a Research Scientist at the New York State Psychiatric Institute (NYSPI) from December 2006 to June 2014. He also served as a member of the Institutional Review Board of the NYSPI from January 2009 to June 2014. As Principal Investigator and Co-Investigator on several human studies of PTSD, Dr. Sullivan has administered the recruitment, biological assessments, treatment, and safety of participants with PTSD in clinical trials of the disorder. He has published more than 50 articles and chapters on research topics ranging from stress and anxiety disorders to abnormal serotonin receptor expression in depression, PTSD and panic disorder. He is a recipient of grants from the National Institute of Mental Health (NIMH), the Anxiety Disorders Association of America, NARSAD, the Dana Foundation, and the American Foundation for Suicide Prevention. Dr. Sullivan received a BA in Biology from the University of California, Berkeley, and received his MD from the College of Physicians & Surgeons at Columbia University. He completed his residency training in psychiatry at CUMC, and then a two-year NIMH-sponsored research fellowship in anxiety and affective disorders before joining the faculty at Columbia.
- Bradley Saenger
Bradley Saenger 2016年2月成为我们的财务总监。自2014年5月起，Saenger先生在Tonix工作，担任会计主任（2014年5月至 2015年12月）和会计副总裁（2016年1月至2016年2月。 2013年6月至2014年3月，Saenger先生在Shire Pharmaceuticals担任财务分析师研究和开发部的一名顾问。自2015年11月起，Saenger先生一直在Tonix Pharma Holdings Limited担任董事。 2013年2月至2013年5月，Saenger先生在Stewart Health Care System担任财务顾问。 2011年10月至2012年12月，Saenger先生是Vertex Pharmaceuticals, Inc.的会计副总监。2005年1月至2011年9月，Saenger先生就职于Alere Inc.，担任公司会计和合并的经理（2007年至 2011 年）和财务报告经理（2005年至2006年）。 Saenger先生还曾任职于PricewaterhouseCoopers LLP；南非约翰内斯堡Shifren Hirsowitz的会计师和审计师；南非约翰内斯堡Investec的投资银行；南非约翰内斯堡的Norman Sifris担任会计师和审计师。 Saenger先生获得了南非大学学士学位和荣誉会计学位。 Saenger先生是南非的一名注册会计师和马萨诸塞州联邦的注册会计师。
Bradley Saenger became our Chief Financial Officer in February 2016. Mr. Saenger has worked for us since May 2014 as the Director of Accounting May 2014 - December 2015 and VP of Accounting (January 2016 - February 2016). Between June 2013 and March 2014 Mr. Saenger worked for Shire Pharmaceuticals as a consultant in the financial analyst research and development group. Since November 2015 Mr. Saenger has been a director of Tonix Pharma Holdings Limited. Between February 2013 and May 2013 Mr. Saenger worked for Stewart Health Care System as a financial consultant. Between October 2011 and December 2012 Mr. Saenger was an Associate Director of Accounting at Vertex Pharmaceuticals, Inc. Between January 2005 and September 2011 Mr. Saenger worked for Alere Inc., as a Manager of Corporate Accounting and Consolidations (2007 - 2011) and Manager of Financial Reporting (2005 - 2006). Mr. Saenger also worked for PricewaterhouseCoopers LLP, Shifren Hirsowitz, public accountants and auditors in Johannesburg, South Africa, Investec Bank in Johannesburg, South Africa and Norman Sifris and Company, public accountants and auditors in Johannesburg, South Africa. Mr. Saenger received his Bachelor’s and Honors’ degrees in Accounting Science from the University of South Africa. Mr. Saenger is a Chartered Accountant in South Africa and a Certified Public Accountant in the Commonwealth of Massachusetts.- Bradley Saenger 2016年2月成为我们的财务总监。自2014年5月起，Saenger先生在Tonix工作，担任会计主任（2014年5月至 2015年12月）和会计副总裁（2016年1月至2016年2月。 2013年6月至2014年3月，Saenger先生在Shire Pharmaceuticals担任财务分析师研究和开发部的一名顾问。自2015年11月起，Saenger先生一直在Tonix Pharma Holdings Limited担任董事。 2013年2月至2013年5月，Saenger先生在Stewart Health Care System担任财务顾问。 2011年10月至2012年12月，Saenger先生是Vertex Pharmaceuticals, Inc.的会计副总监。2005年1月至2011年9月，Saenger先生就职于Alere Inc.，担任公司会计和合并的经理（2007年至 2011 年）和财务报告经理（2005年至2006年）。 Saenger先生还曾任职于PricewaterhouseCoopers LLP；南非约翰内斯堡Shifren Hirsowitz的会计师和审计师；南非约翰内斯堡Investec的投资银行；南非约翰内斯堡的Norman Sifris担任会计师和审计师。 Saenger先生获得了南非大学学士学位和荣誉会计学位。 Saenger先生是南非的一名注册会计师和马萨诸塞州联邦的注册会计师。
- Bradley Saenger became our Chief Financial Officer in February 2016. Mr. Saenger has worked for us since May 2014 as the Director of Accounting May 2014 - December 2015 and VP of Accounting (January 2016 - February 2016). Between June 2013 and March 2014 Mr. Saenger worked for Shire Pharmaceuticals as a consultant in the financial analyst research and development group. Since November 2015 Mr. Saenger has been a director of Tonix Pharma Holdings Limited. Between February 2013 and May 2013 Mr. Saenger worked for Stewart Health Care System as a financial consultant. Between October 2011 and December 2012 Mr. Saenger was an Associate Director of Accounting at Vertex Pharmaceuticals, Inc. Between January 2005 and September 2011 Mr. Saenger worked for Alere Inc., as a Manager of Corporate Accounting and Consolidations (2007 - 2011) and Manager of Financial Reporting (2005 - 2006). Mr. Saenger also worked for PricewaterhouseCoopers LLP, Shifren Hirsowitz, public accountants and auditors in Johannesburg, South Africa, Investec Bank in Johannesburg, South Africa and Norman Sifris and Company, public accountants and auditors in Johannesburg, South Africa. Mr. Saenger received his Bachelor’s and Honors’ degrees in Accounting Science from the University of South Africa. Mr. Saenger is a Chartered Accountant in South Africa and a Certified Public Accountant in the Commonwealth of Massachusetts.
- Jessica Morris
Jessica Morris是我们的首席运营官，自2013年4月以来一直在该公司工作，先是担任顾问，2013年4月至2013年9月，然后担任财务高级副总裁（2013年9月至2015年10月），随后担任首席行政官（2015年10月至2016年1月），代理首席财务官（2016年1月至2016年2月）和运营执行Vice President（2016年2月至2018年1月）。在加入公司之前，Morris女士是Zhong Rong Group投资管理Vice President。此前，莫里斯曾是美国资本公司（American Capital）赞助金融组的高级助理，该公司是卡尔弗特街资本合伙公司（Calvert Street Capital Partners）夹层债务基金的Vice President，也是硅谷银行（Silicon Valley Bank）商业金融部的助理，以及Deutsche Bank投资银行集团金融分析师。Morris女士在弗吉尼亚大学（University of Virginia）获得商业学士学位和音乐学士学位，在那里她是Echols学者。
Jessica Morris is our Chief Operations Officer and has worked for the Company since April 2013 first as a consultant April 2013 - September 2013 then as SVP of Finance (September 2013 - October 2015), followed by Chief Administrative Officer (October 2015 - January 2016), Acting Chief Financial Officer (January 2016 - February 2016), and Executive Vice President, Operations (February 2016 - January 2018). Prior to joining the Company, Ms. Morris was a Vice President in investment management at Zhong Rong Group. Previously, Ms. Morris was a Senior Associate in the Sponsor Finance Group at American Capital, a Vice President of the mezzanine debt fund at Calvert Street Capital Partners, an Associate in the commercial finance department of Silicon Valley Bank, and a Financial Analyst in the investment banking group at Deutsche Bank. Ms. Morris earned a B.S. in Commerce and a B.A. in Music from the University of Virginia, where she was an Echols Scholar.- Jessica Morris是我们的首席运营官，自2013年4月以来一直在该公司工作，先是担任顾问，2013年4月至2013年9月，然后担任财务高级副总裁（2013年9月至2015年10月），随后担任首席行政官（2015年10月至2016年1月），代理首席财务官（2016年1月至2016年2月）和运营执行Vice President（2016年2月至2018年1月）。在加入公司之前，Morris女士是Zhong Rong Group投资管理Vice President。此前，莫里斯曾是美国资本公司（American Capital）赞助金融组的高级助理，该公司是卡尔弗特街资本合伙公司（Calvert Street Capital Partners）夹层债务基金的Vice President，也是硅谷银行（Silicon Valley Bank）商业金融部的助理，以及Deutsche Bank投资银行集团金融分析师。Morris女士在弗吉尼亚大学（University of Virginia）获得商业学士学位和音乐学士学位，在那里她是Echols学者。
- Jessica Morris is our Chief Operations Officer and has worked for the Company since April 2013 first as a consultant April 2013 - September 2013 then as SVP of Finance (September 2013 - October 2015), followed by Chief Administrative Officer (October 2015 - January 2016), Acting Chief Financial Officer (January 2016 - February 2016), and Executive Vice President, Operations (February 2016 - January 2018). Prior to joining the Company, Ms. Morris was a Vice President in investment management at Zhong Rong Group. Previously, Ms. Morris was a Senior Associate in the Sponsor Finance Group at American Capital, a Vice President of the mezzanine debt fund at Calvert Street Capital Partners, an Associate in the commercial finance department of Silicon Valley Bank, and a Financial Analyst in the investment banking group at Deutsche Bank. Ms. Morris earned a B.S. in Commerce and a B.A. in Music from the University of Virginia, where she was an Echols Scholar.
- Seth Lederman
Seth Lederman，2011年10月担任董事长、首席执行官、董事会主席和总裁。2007年6月，Lederman创立Tonix Pharmaceuticals, Inc.（Tonix Sub全资子公司），并担任董事会主席；2010年6月起担任董事长。Lederman是一位拥有关键专利和潜在项目专利的发明家，包括治疗纤维肌痛症TNX-102 SL fibromyalgia、创伤后应激障碍的TNX-102 SL、发作性紧张型头痛 TNX-201以及酒精中毒TNX-301。2010年8月Krele成立，Lederman担任其主席。自2013年4月Tonix Pharmaceuticals （Canada）， Inc.成立起，Lederman担任董事长和总裁；2013年12月起，他担任Tonix Pharmaceuticals （Barbados）， Ltd总裁；2014年12月起，他担任Tonix Pharma Limited和Tonix Pharma Holdings Limited总裁。1996年起，Lederman担任Columbia University副教授。期间，Lederman发现并标明了CD40-ligand的特征，还发明了治疗自身免疫性疾病和移植排斥的治疗候选人。1996年起，Lederman担任L&L Technologies LLC或L&L经理。2007年1月起，Lederman担任Seth Lederman Co, LLC管理成员；2002年去担任Lederman & Co, LLC或Lederman & Co管理成员，两家公司均为生物制药咨询和投资公司。2000年起，Lederman还是Targent Pharmaceuticals, LLC, or Targent管理成员；2002年起，他是Plumbline LLC管理成员。2001年，Targent创立Targent Pharmaceuticals Inc.并担任董事会成员直到2006年被Spectrum Pharmaceuticals Inc.收购。2007年1月到2008年11月，Lederman是Konanda Pharma Partners, LLC执行合伙人、Konanda Pharma Fund I, LP董事长以及Konanda General Partner, LLC普通合伙人，它们都是相互关联的私人股本基金实体。2007年1月到2008年11月，Lederman是Validus Pharmaceuticals, Inc.和Fontus Pharmaceuticals, Inc.主席，它们是Konanda私人增长股票型基金投资组合公司。2011年12月起，Lederman担任Leder Laboratories Inc.，或Leder Labs, and Starling Pharmaceuticals Inc.或Starling（均为生物制药开发公司）首席执行官和主席。2013年3月起，Lederman担任Leder Laboratories, Ltd.（Leder Laboratories Inc.全资子公司）主席；2006年到2011年，他是Research Corporation（一个总部位于纽约的非营利性组织）董事长。1979年，Lederman获得Princeton University化学学士学位；1983年，他获得Columbia University硕士学位。1985年起，Lederman成为纽约州注册医生。
Seth Lederman became our President, Chief Executive Officer, Chairman of the Board and a Director in October 2011. Dr. Lederman founded Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of us “Tonix Sub” in 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since 2010. Dr. Lederman is an inventor on key patents and patent applications underlying our programs including: TNX-102 SL’s eutectic composition; TNX-102 SL’s pharmacokinetic profile and related therapeutic properties, and the use of TNX-102 SL for posttraumatic stress disorder (PTSD). Dr. Lederman served as an Associate Professor at Columbia University, between 1996 and 2017. As an Assistant Professor at Columbia, Dr. Lederman discovered and characterized the CD40-ligand, or CD154 and invented therapeutic candidates to treat autoimmune diseases and transplant rejection. TNX-1500 is a monoclonal antibody directed against CD154 invented by Dr. Lederman. Dr. Lederman has been a Manager of L&L Technologies LLC, or L&L, since 1996. In addition, Dr. Lederman has been the Managing Member of Seth Lederman Co, LLC since 2007 and the Managing Member of Lederman & Co, LLC, or Lederman & Co, since 2002 both of which are biopharmaceutical consulting and investing companies. Dr. Lederman has also been the Managing Member of Targent Pharmaceuticals, LLC, or Targent, since 2000 and Managing Member of Plumbline LLC since 2002. Targent was a founder of Targent Pharmaceuticals Inc. on which Board of Directors Dr. Lederman served from inception in 2001 until the sale of its assets to Spectrum Pharmaceuticals Inc. in 2006. Between January 2007 and November 2008 Dr. Lederman was a Managing Partner of Konanda Pharma Partners, LLC, a Director of Konanda Pharma Fund I, LP, and a Managing Partner of Konanda General Partner, LLC, which were related private growth equity fund entities. As well, between 2007 and 2008 Dr. Lederman was Chairman of Validus Pharmaceuticals, Inc. and Fontus Pharmaceuticals, Inc., which were portfolio companies of the Konanda private growth equity funds. Since 2011 Dr. Lederman has served as CEO and Chairman of Leder Laboratories Inc., or Leder Labs, and Starling Pharmaceuticals Inc., or Starling, which are biopharmaceutical development companies. Dr. Lederman was the chairman of Leder Laboratories, Ltd., a wholly-owned subsidiary of Leder Laboratories Inc., between 2013 and 2018 when the entity was dissolved. In 2015 Dr. Lederman served as a member of the US - Japan Business Council. Between 2006 and 2011 Dr. Lederman was a director of Research Corporation, a New York-based non-profit organization. Dr. Lederman received his BA degree in Chemistry from Princeton University in 1979 and his MD from Columbia University in 1983.- Seth Lederman，2011年10月担任董事长、首席执行官、董事会主席和总裁。2007年6月，Lederman创立Tonix Pharmaceuticals, Inc.（Tonix Sub全资子公司），并担任董事会主席；2010年6月起担任董事长。Lederman是一位拥有关键专利和潜在项目专利的发明家，包括治疗纤维肌痛症TNX-102 SL fibromyalgia、创伤后应激障碍的TNX-102 SL、发作性紧张型头痛 TNX-201以及酒精中毒TNX-301。2010年8月Krele成立，Lederman担任其主席。自2013年4月Tonix Pharmaceuticals （Canada）， Inc.成立起，Lederman担任董事长和总裁；2013年12月起，他担任Tonix Pharmaceuticals （Barbados）， Ltd总裁；2014年12月起，他担任Tonix Pharma Limited和Tonix Pharma Holdings Limited总裁。1996年起，Lederman担任Columbia University副教授。期间，Lederman发现并标明了CD40-ligand的特征，还发明了治疗自身免疫性疾病和移植排斥的治疗候选人。1996年起，Lederman担任L&L Technologies LLC或L&L经理。2007年1月起，Lederman担任Seth Lederman Co, LLC管理成员；2002年去担任Lederman & Co, LLC或Lederman & Co管理成员，两家公司均为生物制药咨询和投资公司。2000年起，Lederman还是Targent Pharmaceuticals, LLC, or Targent管理成员；2002年起，他是Plumbline LLC管理成员。2001年，Targent创立Targent Pharmaceuticals Inc.并担任董事会成员直到2006年被Spectrum Pharmaceuticals Inc.收购。2007年1月到2008年11月，Lederman是Konanda Pharma Partners, LLC执行合伙人、Konanda Pharma Fund I, LP董事长以及Konanda General Partner, LLC普通合伙人，它们都是相互关联的私人股本基金实体。2007年1月到2008年11月，Lederman是Validus Pharmaceuticals, Inc.和Fontus Pharmaceuticals, Inc.主席，它们是Konanda私人增长股票型基金投资组合公司。2011年12月起，Lederman担任Leder Laboratories Inc.，或Leder Labs, and Starling Pharmaceuticals Inc.或Starling（均为生物制药开发公司）首席执行官和主席。2013年3月起，Lederman担任Leder Laboratories, Ltd.（Leder Laboratories Inc.全资子公司）主席；2006年到2011年，他是Research Corporation（一个总部位于纽约的非营利性组织）董事长。1979年，Lederman获得Princeton University化学学士学位；1983年，他获得Columbia University硕士学位。1985年起，Lederman成为纽约州注册医生。
- Seth Lederman became our President, Chief Executive Officer, Chairman of the Board and a Director in October 2011. Dr. Lederman founded Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of us “Tonix Sub” in 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since 2010. Dr. Lederman is an inventor on key patents and patent applications underlying our programs including: TNX-102 SL’s eutectic composition; TNX-102 SL’s pharmacokinetic profile and related therapeutic properties, and the use of TNX-102 SL for posttraumatic stress disorder (PTSD). Dr. Lederman served as an Associate Professor at Columbia University, between 1996 and 2017. As an Assistant Professor at Columbia, Dr. Lederman discovered and characterized the CD40-ligand, or CD154 and invented therapeutic candidates to treat autoimmune diseases and transplant rejection. TNX-1500 is a monoclonal antibody directed against CD154 invented by Dr. Lederman. Dr. Lederman has been a Manager of L&L Technologies LLC, or L&L, since 1996. In addition, Dr. Lederman has been the Managing Member of Seth Lederman Co, LLC since 2007 and the Managing Member of Lederman & Co, LLC, or Lederman & Co, since 2002 both of which are biopharmaceutical consulting and investing companies. Dr. Lederman has also been the Managing Member of Targent Pharmaceuticals, LLC, or Targent, since 2000 and Managing Member of Plumbline LLC since 2002. Targent was a founder of Targent Pharmaceuticals Inc. on which Board of Directors Dr. Lederman served from inception in 2001 until the sale of its assets to Spectrum Pharmaceuticals Inc. in 2006. Between January 2007 and November 2008 Dr. Lederman was a Managing Partner of Konanda Pharma Partners, LLC, a Director of Konanda Pharma Fund I, LP, and a Managing Partner of Konanda General Partner, LLC, which were related private growth equity fund entities. As well, between 2007 and 2008 Dr. Lederman was Chairman of Validus Pharmaceuticals, Inc. and Fontus Pharmaceuticals, Inc., which were portfolio companies of the Konanda private growth equity funds. Since 2011 Dr. Lederman has served as CEO and Chairman of Leder Laboratories Inc., or Leder Labs, and Starling Pharmaceuticals Inc., or Starling, which are biopharmaceutical development companies. Dr. Lederman was the chairman of Leder Laboratories, Ltd., a wholly-owned subsidiary of Leder Laboratories Inc., between 2013 and 2018 when the entity was dissolved. In 2015 Dr. Lederman served as a member of the US - Japan Business Council. Between 2006 and 2011 Dr. Lederman was a director of Research Corporation, a New York-based non-profit organization. Dr. Lederman received his BA degree in Chemistry from Princeton University in 1979 and his MD from Columbia University in 1983.